Improved survival prediction for oropharyngeal cancer beyond TNMv8. (April 2021)

• Record Type: Journal Article
• Authors: Price, J.M.; West, C.M.; Mistry, H.B.; Betts, G.; Bishop, P.; Kennedy, J.; Dixon, L.; Homer, J.J.; Garcez, K.P.; Lee, L.W.; McPartlin, A.; Sykes, A.J.; Thomson, D.J.
• Is Part Of: Oral oncology. Volume 115(2021)
• Publication Date: 2021-04
• Subjects: Head and Neck Cancer -- Oropharyngeal cancer -- P16 -- Staging -- TNM -- Overall survival -- Survival prediction -- Nomogram -- Prognostic; Mouth -- Cancer -- Periodicals; Mouth -- Tumors -- Periodicals; Mouth Diseases -- Periodicals; Mouth Neoplasms -- Periodicals; Bouche -- Cancer -- Périodiques; Bouche -- Tumeurs -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9943105
• DOI: 10.1016/j.oraloncology.2020.105140
• Languages: English
• ISSNs: 1368-8375

Abstract

Highlights: AJCC/UICC TNM version 8 is superior to TNM version 7 for p16-positive oropharyngeal cancer. Both TNM versions 7 and 8 demonstrates poor hazard discrimination for p16-negative disease. Adjustments to T, N stage and p16-status groupings did not improve prognostication. A novel nomogram improved 5-year overall survival prediction beyond TNM version 8. Abstract: Purpose: For oropharynx squamous cell carcinoma (OPSCC) this study aimed to: (i) compare 5-year overall survival (OS) stratification by AJCC/UICC TNM versions 7 (TNMv7) and 8 (TNMv8), (ii) determine whether changes to T and N stage groupings improve prognostication and (iii) develop and validate a model incorporating additional clinical characteristics to improve 5-year OS prediction. Material and Methods: All OPSCC treated with curative-intent at our institution between 2011 and 2017 were included. The primary endpoint was 5-year OS. Survival curves were produced for TNMv7 and TNMv8. A three-way interaction between T, N stage and p16 status was evaluated for improved prognostication. Cox proportional hazards modelling was used to derive a new predictive model. Results: Of 750 OPSCC cases, 574 (77%) were p16-positive. TNMv8 was more prognostic than TNMv7 (concordance probability estimate [CPE] ± SE = 0.72 ± 0.02 vs 0.53 ± 0.02). For p16-positive disease, TNMv8 discriminated stages II vs I (HR 2.32, 95% CI 1.47–3.67) and III vs II (HR 1.75, 95% CI 1.13–2.72). For p16-negative disease, TNMv7 and TNMv8 demonstrated poor hazard discrimination. Different T, N stage and p16-status combinations did not improve prognostication after adjusting for other factors (CPE = 0.79 vs 0.79, p = 0.998). A model for p16-positive and p16-negative OPSCC including additional clinical characteristics improved 5-year OS prediction beyond TNMv8 (c-index 0.76 ± 0.02). Conclusions: TNMv8 is superior to TNMv7 for p16-positive OPSCC, but both performed poorly for p16-negative disease. A novel model incorporating additional clinical characteristics improved 5-year OS prediction for both p16-positive and p16-negative disease.